BackObalon Therapeutics Overview

Obalon Therapeutics Intangible Assets

Latest intangible assets for OBLN: $310K.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$314191.00

Peer average

Loading

Obalon Therapeutics Intangible Assets History

Loading

Obalon Therapeutics vs. peers: Intangible Assets Comparison

Loading

Obalon Therapeutics Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Obalon Therapeutics (OBLN) FAQ

As of the most recent data (March 2026), OBLN shows a intangible assets of $310K. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, OBLN's intangible assets is now $310K (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Obalon Therapeutics is outperforming or lagging.

Tracking OBLN's intangible assets over time shows whether Obalon Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $310K In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Obalon Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $310K) with ownership activity and broader fundamentals.

Obalon Therapeutics's intangible assets is $310K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.